Project Grant R41CA284997
Award Date
6/1/25
Completion Date
5/31/26
Dollars Obligated
$400K
Federal Agency
National Cancer Institute
Awardee
Oncotab, Inc. (E5FXNY7GG5M5)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $269,280 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Translational Genomics Research Institute (TGen) to conduct research aimed at improving the treatment of pancreatic ductal adenocarcinoma (PDAC). The project will evaluate the biological effects and antitumor activity of a senescent cell-targeted antibody, SIWA318, in preclinical PDAC models. Specifically, the research will determine if SIWA318 can remodel the tumor...
The National Cancer Institute awarded Oncotrap Inc. a $400,000 Project Grant to develop an aptamer-directed IgG1-Fc drug conjugate (AFDC) platform for the treatment of pancreatic ductal adenocarcinoma (PDAC). The project aims to validate the ability of the APTPDAC aptamer to selectively kill PDAC cells and create a potent AFDC targeting PDAC cells. Additionally, the project will evaluate the in vivo anti-tumor efficacy of the AFDC in PDAC mouse models and identify the target cell surface...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop a novel targeted therapeutic strategy against metastatic pancreatic ductal adenocarcinoma (PDAC) using a newly developed monoclonal antibody (AREMAB6) that targets the cancer-specific Tn antigen. The $1,130,538 award to the University of Louisville, with the Board of Regents of the University of Nebraska as the parent organization, will fund research to: Determine the...
This Project Grant award from the National Cancer Institute (NCI) under CFDA Program 93.395 (Cancer Treatment Research) provides $400,835 to Cambium Oncology LLC to develop a novel Chimeric Antigen Receptor (CAR) T-cell immunotherapy for the treatment of pancreatic ductal adenocarcinoma (PDAC). The two-phase project aims to engineer CAR T-cells that secrete a Vasoactive Intestinal Peptide (VIP) receptor antagonist to counteract the immunosuppressive tumor microenvironment of PDAC. Phase 1 will...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $402,401 to Emory University to develop a PET CCR2 imaging agent to profile the pancreatic ductal adenocarcinoma (PDAC) microenvironment. The funding period runs from July 4, 2024 to June 30, 2026. The project aims to create an innovative PET imaging agent capable of visualizing CCR2, a key molecular target associated with the PDAC tumor microenvironment. By profiling...
The National Cancer Institute (NCI) awarded a $399,970 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Duo Oncology Inc. to develop DUO-207, an ultrasmall nanoparticle drug combination therapy for the treatment of advanced pancreatic cancer. The proposed innovation aims to improve the efficacy and safety of current standard-of-care treatments by enhancing the delivery and release of the active drug components gemcitabine and paclitaxel. Key innovations include a...
This $431,561 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by The Johns Hopkins University to elucidate mechanisms by which the HMGA1 chromatin regulator drives pancreatic ductal adenocarcinoma (PDAC) progression and tumor microenvironment signaling. The research aims to 1) precisely define HMGA1-dependent mechanisms in PDAC tumor progression using mouse models and primary human tumors, and 2) test targeting HMGA1 pathways for...
This federal Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $674,275 to Marker Therapeutics Inc., a self-certified small disadvantaged biotechnology company, to conduct a Phase 1 clinical study on their MT-601 T-cell immunotherapy product for the treatment of metastatic pancreatic cancer. The grant funds a 3-year research project to evaluate the safety and efficacy of administering MT-601 in combination with standard-of-care...
This federal Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) totaling $351,131 provides funding to the University of Miami to conduct research aimed at overcoming chemotherapy and immunotherapy resistance in pancreatic cancer. The key products and services to be delivered under this 5-year project include: Mechanistically dissecting the signaling interactions and spatial relationships between immunosuppressive myeloid-derived suppressor...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $677,176 to The Research Foundation For The State University Of New York to conduct research on interstitial chemophototherapy (I-CPT) as an intervention for locally advanced pancreatic cancer. The key products and services to be delivered under this grant include: Defining the optimal light dosimetry for I-CPT in preclinical models of locally advanced pancreatic cancer, including...